Fungal Cell Wall: Emerging Antifungals and Drug Resistance

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2019 Dec 12

PMID 31824443

Citations 65

Authors

Soraia L Lima

Arnaldo L Colombo

Joao N de Almeida Junior

Affiliations

Soon will be listed here.

Abstract

The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in human cells makes this component an attractive target for antifungal development. The host environment and antifungal stress can lead to cell wall modifications related to drug resistance. Antifungals targeting the cell wall including the new β-D-glucan synthase inhibitor ibrexafungerp and glycosyl-phosphatidyl Inositol (GPI) anchor pathway inhibitor fosmanogepix are promising weapons against antifungal resistance. The fosmanogepix shows strong activity against the multidrug-resistant species , , and The alternative carbon sources in the infection site change the cell wall β-D-glucan and chitin composition, leading to echinocandin and amphotericin resistance. populations that survive echinocandin exposure develop tolerance and show high chitin content in the cell wall, while fungal species such as with a higher β-D-glucan content may show amphotericin resistance. Therefore understanding fungal cell dynamics has become important not only for host-fungal interactions, but also treatment of fungal infections. This review summarizes recent findings regarding antifungal therapy and development of resistance related to the fungal cell wall of the most relevant human pathogenic species.

Citing Articles

The multidrug-resistant complex and phylogenetic related species: Insights into antifungal resistance mechanisms.

Ramos L, Barbosa P, Lorentino C, Lima J, Braga A, Lima R Curr Res Microb Sci. 2025; 8:100354.

PMID: 39995443 PMC: 11847750. DOI: 10.1016/j.crmicr.2025.100354.

Bacillus velezensis CE 100 controls anthracnose disease in walnut trees (Juglans regia L.) by inhibiting Colletotrichum gloeosporioides and eliciting induced systemic resistance.

Choub V, Won S, Moon J, Choi S, Ajuna H, Ahn Y Biotechnol Lett. 2025; 47(1):20.

PMID: 39907859 DOI: 10.1007/s10529-025-03560-0.

Baicalin promotes β-1,3-glucan exposure in and enhances macrophage response.

Pan Y, Shi Z, Wang Y, Chen F, Yang Y, Ma K Front Cell Infect Microbiol. 2024; 14:1487173.

PMID: 39717547 PMC: 11664218. DOI: 10.3389/fcimb.2024.1487173.

Versus Chitinase as an Anti-inflammatory and Antifungal Agent Against Human Pathogenic Fungi.

Abdelraouf A, Al-Hazmi N, Naguib D Indian J Microbiol. 2024; 64(4):1863-1869.

PMID: 39678951 PMC: 11645452. DOI: 10.1007/s12088-024-01253-2.

MaPom1, a Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase, Positively Regulates Thermal and UV-B Tolerance in .

Zhang Y, Song L, Xia Y Int J Mol Sci. 2024; 25(22).

PMID: 39595934 PMC: 11594272. DOI: 10.3390/ijms252211860.

References

Pfaller M, Messer S, Rhomberg P, Borroto-Esoda K, Castanheira M . Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527608. DOI: 10.1128/AAC.00161-17. View

Hector R . Compounds active against cell walls of medically important fungi. Clin Microbiol Rev. 1993; 6(1):1-21. PMC: 358263. DOI: 10.1128/CMR.6.1.1. View

Thompson 3rd G, Barker B, Wiederhold N . Large-Scale Evaluation of Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365710. DOI: 10.1128/AAC.02634-16. View

Scorneaux B, Angulo D, Borroto-Esoda K, Ghannoum M, Peel M, Wring S . SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Antimicrob Agents Chemother. 2017; 61(3). PMC: 5328566. DOI: 10.1128/AAC.01961-16. View

Ikezawa H . Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm Bull. 2002; 25(4):409-17. DOI: 10.1248/bpb.25.409. View

Roy R, Klein B . Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe. 2012; 11(5):436-46. PMC: 3401965. DOI: 10.1016/j.chom.2012.04.005. View

Goldberg J, Connolly P, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M . Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob Agents Chemother. 2000; 44(6):1624-9. PMC: 89923. DOI: 10.1128/AAC.44.6.1624-1629.2000. View

Espinel-Ingroff A . In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2004; 20(4):121-36. View

Shaw K, Schell W, Covel J, Duboc G, Giamberardino C, Kapoor M . and Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105804. DOI: 10.1128/AAC.00523-18. View

10.

Gow N, Latge J, Munro C . The Fungal Cell Wall: Structure, Biosynthesis, and Function. Microbiol Spectr. 2017; 5(3). PMC: 11687499. DOI: 10.1128/microbiolspec.FUNK-0035-2016. View

11.

Mazur P, Baginsky W . In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1. J Biol Chem. 1996; 271(24):14604-9. DOI: 10.1074/jbc.271.24.14604. View

12.

Ruping M, Vehreschild J, Farowski F, Cornely O . Anidulafungin: advantage for the newcomer?. Expert Rev Clin Pharmacol. 2014; 1(2):207-16. DOI: 10.1586/17512433.1.2.207. View

13.

Arendrup M, Chowdhary A, Astvad K, Jorgensen K . APX001A Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153824. DOI: 10.1128/AAC.01225-18. View

14.

Singh S, Robbins N, Zaas A, Schell W, Perfect J, Cowen L . Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 2009; 5(7):e1000532. PMC: 2712069. DOI: 10.1371/journal.ppat.1000532. View

15.

Shibata N, Ikuta K, Imai T, Satoh Y, Satoh R, Suzuki A . Existence of branched side chains in the cell wall mannan of pathogenic yeast, Candida albicans. Structure-antigenicity relationship between the cell wall mannans of Candida albicans and Candida parapsilosis. J Biol Chem. 1995; 270(3):1113-22. DOI: 10.1074/jbc.270.3.1113. View

16.

Cordeiro R, Brilhante R, Rocha M, Fechine M, Costa A, Camargo Z . In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from Northeast, Brazil. Mycopathologia. 2006; 161(1):21-6. DOI: 10.1007/s11046-005-0177-0. View

17.

Sandison T, Ong V, Lee J, Thye D . Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Antimicrob Agents Chemother. 2016; 61(2). PMC: 5278714. DOI: 10.1128/AAC.01627-16. View

18.

Watanabe N, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K . E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2011; 56(2):960-71. PMC: 3264227. DOI: 10.1128/AAC.00731-11. View

19.

Hager C, Larkin E, Long L, Ghannoum M . Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018; 73(8):2085-2088. PMC: 6070025. DOI: 10.1093/jac/dky153. View

20.

Satish S, Jimenez-Ortigosa C, Zhao Y, Lee M, Dolgov E, Kruger T . Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus. mBio. 2019; 10(3). PMC: 6550521. DOI: 10.1128/mBio.00779-19. View